Skip to main navigation Skip to search Skip to main content

Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy

  • David B. Olawade
  • , Emmanuel O. Oisakede
  • , Eghosasere Egbon
  • , Saak V. Ovsepian
  • , Stergios Boussios
  • University of East London
  • Leeds Teaching Hospitals NHS Trust
  • Department of Tissue Engineering and Regenerative Medicine
  • University of Greenwich London
  • Department of Research and Innovation
  • Medway NHS Foundation Trust
  • Swedish School of Sport and Health Sciences
  • University of Ioannina
  • Department of Medical Oncology
  • Ioannina University Hospital
  • Faculty of Life Sciences & Medicine
  • School of Cancer & Pharmaceutical Sciences
  • King's College London
  • AELIA Organization

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Immune organoids have emerged as a ground-breaking platform in immunology, offering a physiologically relevant and controllable environment to model human immune responses and evaluate immunotherapeutic strategies. Derived from stem cells or primary tissues, these three-dimensional constructs recapitulate key aspects of lymphoid tissue architecture, cellular diversity, and functional dynamics, providing a more accurate alternative to traditional two-dimensional cultures and animal models. Their ability to mimic complex immune microenvironments has positioned immune organoids at the forefront of cancer immunotherapy development, autoimmune disease modeling, and personalized medicine. This narrative review highlights the advances in immune organoid technology, with a focus on their applications in testing immunotherapies, such as checkpoint inhibitors, CAR-T cells, and cancer vaccines. It also explores how immune organoids facilitate the study of autoimmune disease pathogenesis with insights into their molecular basis and support in high-throughput drug screening. Despite their transformative potential, immune organoids face significant challenges, including the replication of systemic immune interactions, standardization of fabrication protocols, scalability limitations, biological heterogeneity, and the absence of vascularization, which restricts organoid size and maturation. Future directions emphasize the integration of immune organoids with multi-organ systems to better replicate systemic physiology, the development of advanced biomaterials that closely mimic lymphoid extracellular matrices, the incorporation of artificial intelligence (AI) to optimize organoid production and data analysis, and the rigorous clinical validation of organoid-derived findings. Continued innovation and interdisciplinary collaboration will be essential to overcome existing barriers, enabling the widespread adoption of immune organoids as indispensable tools for advancing immunotherapy, vaccine development, and precision medicine.
Original languageEnglish
Pages (from-to)653
Number of pages1
JournalCurrent Issues in Molecular Biology
Volume47
Issue number8
DOIs
Publication statusPublished - 13 Aug 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Immune organoids
  • Cancer immunotherapy
  • Autoimmune diseases
  • Precision medicine
  • Bioengineering

Fingerprint

Dive into the research topics of 'Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy'. Together they form a unique fingerprint.

Cite this